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Acute kidney injury (AKI) is a commoncomplication during inpatient hospitalization,and clinicaloutcomes remainpoor despite
advancements in renal replacement therapy. AKI in the setting of multiple organ failure (MOF) remains a formidable challenge
to clinicians and incurs an unacceptably high mortality rate. Kidney ischemia-reperfusion injury (IRI) incites a proinﬂammatory
cascade and releases cellular and soluble mediators with systemic implications for remote organ injury. Evidence from preclinical
models cites mechanisms of organ crosstalk during ischemic AKI including the expression of cellular adhesion molecules,
lymphocyte traﬃcking, release of proinﬂammatory cytokines and chemokines, and modiﬁcation of the host innate and adaptive
immune response systems. In this paper, the inﬂuence of kidney IRI on systemic inﬂammation and distant organ injury will be
examined. Recent experimental data and evolving concepts of organ crosstalkduring ischemic AKI will also be discussed in detail.
1.Introduction
Despite advancements in renal replacement therapy, acute
kidney injury (AKI) is a frequent complication with severe
implications for the critically ill patient. Published mortality
rates for intensive care unit patients with AKI range between
30and 70%,and AKIalone remains an independentrisk fac-
torformortalityevenafteradjustmentfordemographicsand
severity of illness [1, 2]. Kidney ischemia-reperfusion injury
(IRI) occurs in various clinical settings including shock,
sepsis, organ transplantation, and vascular surgery. AKI,
however, rarely occurs in isolation. It has become apparent
that clinically much of the high patient mortality can be at-
tributed to the onset of systemic inﬂammatory response
syndrome (SIRS) and progression to multiple organ failure
(MOF).
Sincethe1950s, clinicianshaveidentiﬁedabnormal chest
radiographs in patients with chronic kidney failure. Pul-
monary dysfunction was thought to result from “increased
permeability of congested pulmonary capillaries,” and this
was dubbed the “uremic lung” [3]. Even in the acute setting,
however, kidney dysfunction directly contributes to the
onset of remote organ injury. For example, increased kidney
ischemia time during complex aortic surgery is associated
not only with acute and chronic renal failure, but also with
an increased incidence of remote organ injury and death [4–
6].
Clinical and translational laboratory studies have
demonstrated the relevance of interactions between the
injured kidneyand distant organs, and complexmechanisms
of crosstalk between injured kidneys and remote organs
s u c ha st h el u n g s ,l i v e r ,h e a r t ,g u t ,b r a i n ,a n dh e m a t o l o g i c
system have been identiﬁed. Recent data highlights the
importance of both the innate and adaptive immune
response, activation of proinﬂammatory cascades, and
an alteration of transcriptional events in remote organs
during ischemic AKI. The purpose of this paper is to
review emerging concepts of organ crosstalk and recent
experimental data regarding the activation and systemic
expression of proinﬂammatory pathways during ischemic
AKI. For a complete list of abbreviations used in this paper,
please see Table 1.2 International Journal of Nephrology
Table 1: Abbreviations.
α-MSH α-Melanocyte-stimulating hormone
AKI Acute kidney injury
ALI Acute lung injury
AP-1 Activator protein-1
ARDS Acute respiratory distress syndrome
CNS Central nervous system
G-CSF Granulocyte colony-stimulating factor
GFAP Glial ﬁbrillary acidic protein
HSC Hepatic stellate cell
ICAM-1 Intercellular adhesion molecule-1
IL-1 Interleukin-1
Il1r2 Interleukin-1 receptor type II
IRI Ischemia-reperfusion injury
KC Keratinocyte chemoattractant
KC/CXCL1 Keratinocyte-derived chemokine
MIP-2/CXCL-2 Macrophage inﬂammatory protein
MOF Multiple organ failure
NF-κBN u c l e a r f a c t o r - κB
Ngp Neutrophilic granule protein
Saa3 Serum amyloid A3
SIRS Systemic inﬂammatory response syndrome
TCR T-cell receptor
TLR Toll-like receptor
TNFR1 Tumor necrosis factor receptor-1
TNFα Tumor necrosis factor-α
2.Ischemic AKI
Kidney IRI remains a major cause of AKI in both native
and transplanted organs and lacks a speciﬁc treatment aside
from renal replacement therapy. The local eﬀects of kidney
IRI begin in the most vulnerable regions of the organ, after
which a cascade of microvascular inﬂammation propagates.
Although 25% of cardiac output contributes to renal blood
ﬂow, only a fraction ultimately reaches the vasa recta of the
renal medulla, with the majority reaching the renal cortex
[7].Therefore,evenslightalterationsintotalrenalbloodﬂow
may lead to anoxic injury in the medulla, resulting in tubular
dysfunction, salt wasting, and glomerular vasoconstriction
through tubuloglomerular feedback [8, 9].
Kidney IRI activates an inﬂammatory response which
results in endothelial cell activation, leukocyte adhesion and
entrapment, and compromised microvascular blood ﬂow
[10]. Inﬂammation in the postischemic kidney triggers the
upregulation of leukocyte adhesion molecules, toll-like
receptors, and downstream transcription factors, which all
contribute to disruption of the integrity of the renal vascular
endothelium[11]. Adhesion molecules such as integrins and
selectins along with proinﬂammatory cytokines propagate
cellular injury not only locally in the renal tubular epithelial
cellsbutalso travel to remote organs where genomicmarkers
of injury are upregulated and phenotypic injury occurs [12].
Unfortunately, selective inhibition ofcytokinesand adhesion
molecules such as tumor necrosis factor-α (TNF-α)a n d
intercellular adhesion molecule (ICAM-1) have failed to
demonstrate global attenuation of both local and remote
organ injury during experimental models of ischemic AKI
[13–16]. However, α-melanocyte-stimulating hormone (α-
MSH), a cytokine with broad antiinﬂammatory, anticyto-
toxic, and antiapoptotic properties, has demonstrated suc-
cess in treating the inﬂammatory phenotype in rodents. In
this model, treatment with α-MSH has attenuated both renal
and pulmonary injury during ischemic AKI [13, 17].
The largely unsuccessful eﬀort to ameliorate MOF
with speciﬁc anti-inﬂammatory therapeutics highlights the
complexity of the systemic response to kidney IRI. From
these early experimental studies, it is possible that the
multiple inﬂammatory pathways activated in each organ
system represent a unique response to ischemic AKI.
Despite a paucity of data, several diﬀerent pathophysiologic
responses to ischemic AKI in remote organs have been
identiﬁed (Figure 1). In the heart, increased expression of
TNFα and interleukin-1 (IL-1) are associated with myocyte
apoptosis. In the brain, increased expression of chemokines
including keratinocyte chemoattractant (KC, a brain IL-
8 homologue) and granulocyte colony-stimulating factor
(G-CSF) are seen with increased vascular permeability.
Additional responses in the lungs, gut, and liver have been
discovered, and these individual organ responses will be
detailed later in this paper. We will now focus on cellular
mediators, speciﬁcally those involved in the innate and
adaptive immune system, which may connect local ischemic
AKI with distant organ injury.
2.1. Innate Immunity. The innate immune system plays an
important role in mediating the inﬂammatory response
during ischemic AKI. Traditionally, innate immunity elicits
an immediate, preprogrammed response to tissue injury
that lacks immunologic memory. It is composed of plasma
proteins(complement),cells(neutrophils,macrophages,and
natural killercells), and physical barriers. Proposed initiators
of the innate immune response during IRI include the
activation of toll-like receptors (TLRs) and the release of
reactive oxygen species (nitric oxide and superoxide anion)
and mitochondrial products [18]. The complement system,
particularly the alternative pathway, is activated, stimulating
releaseofcytokinesandsubsequentactivationofneutrophils,
endothelium, and macrophages [19].
TLRsareafamilyoftransmembraneproteinswhichserve
as major pattern recognition receptors, binding to a wide
rangeofmicrobialproductsandendogenousligandsreleased
as a consequence of injury. TLR-dependent signaling serves
as a rapid response mechanism to local tissue damage and
has been implicated in early activation of the innate immune
response during kidney IRI [11, 20]. Renal tubular epithelial
cellsconstitutivelyexpressTLR2and TLR4,and IRIresultsin
selective upregulationof these TLRs. Experimental studies of
kidneyIRIhavedemonstrated attenuationofrenal structural
and functional injury in both TLR2−/− and TLR4−/−mice,
implicating TLR2 and TLR4 signaling in renal damage [21,
22]. TLR2 may also play a role in transplantation toleranceInternational Journal of Nephrology 3
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Figure1:AKIandorgancrosstalk.AKIinducesremoteorganinjuryintheheart,brain,lungs,liver,andgutinvolvingmultipleinﬂammatory
pathways, including increased expression of soluble proinﬂammatory mediators, innate and adaptive immunity, cellular apoptosis, physio-
logic derangements and genomic changes.
by decreasing the inﬁltration of T cells, dendritic cells, and
macrophages [23].
T cells may act during early IRI despite lacking alloanti-
genic stimulation, which challenges the traditional function
of T cells as exclusive mediators of the adaptive immune
response [19]. Signiﬁcant evidence exists to support the
role of T cells in gut, heart, and lung ischemia-reperfusion
injury [24–28]. Likewise, experimental data also points
toward antigen-independent T-cell activation in ischemic
AKI through cytokines secreted by macrophages and den-
dritic cells, chemokines, oxygen free radicals and the com-
plement system [7, 19, 29].
Speciﬁc populations of T cells likely contribute to injury
in unique ways. For example, mice deﬁcient in CD4+ and
CD8+ cells and athymic mice demonstrate protection from
experimental ischemic AKI; however, only adoptive transfer
of T cells of the CD4+ type restores this injury [30, 31].
Not all T cells, however, perpetuate inﬂammatory damage
during ischemic AKI; some populations of T cells confer
renal protection after IRI, particularly the Th2 phenotype of
CD4+ T cells and T regulatory cells [32]. Additional recent
experimentaldatahascharacterized speciﬁc populationsofT
lymphocytes traﬃcking to remote organs that may facilitate
organ crosstalk during ischemic AKI. In a rodent model
of kidney IRI, a distinct inﬂux of CD3+ (T) cells with
a predominant CD8+ T cell subpopulation was identiﬁed
24hours after experimental kidney IRI. These pulmonary
T cells acquired increased expression of activation markers
suggesting that ischemic AKI induced traﬃcking of activated
T cells which contributed to pulmonary injury, speciﬁcally
apoptosis [33]. The speciﬁc role of subpopulations of T cells
in the pathogenesis of ischemic AKI remains a stimulating
topic of current and future investigation, both in the innate
and adaptive immune response to kidney IRI.
2.2. Adaptive Immunity. The adaptive immune system relies
on the speciﬁcity of antigen receptors on both B and T
cells that respond to millions of various antigenic molec-
ular structures. Once stimulated by an antigen, B cells
(humoral immunity) produce speciﬁc antibodies, perform
opsonization to facilitate phagocytosis, and activate the
complement system. The T-cell receptor (TCR) responds to
presented antigen peptides by activating macrophages to kill
phagocytosedmicrobes,directlydestroyinginfectedcellsand
by releasing cytokines to promote further response (cell-
mediated immunity).
Antigen-dependent T-cell activation has been demon-
strated in experimental models of renal IRI [34, 35]. For
example, mice with a restricted TCR cell repertoire suﬀer4 International Journal of Nephrology
less injury and promote a far diminished inﬂammatory
response during renal IRI. Additionally, athymic mice that
subsequently underwent adoptive transfer with these TCR-
restricted T cells failed to restore injury as severely as seen
with transfer of wild-type T-cells [36]. T cells also play a role
in long term renal modiﬁcation, as an increased number
of both activated and eﬀector-memory T cells have been
observed in postischemic kidneys as long as 6 weeks after IRI
[37]. These T cells may in fact recognize antigens released
during kidney IRI and subsequently target the kidney in
an autoimmune response, leading to long-term progression
of renal dysfunction. This hypothesis was demonstrated
in a murine adoptive transfer model in which na¨ ıve mice
received T cells from mice who were 6weeks after kidney
IRI and subsequently developed albuminuria [38]. Little is
known about the role of B cells in renal IRI; however, B-
cell-deﬁcientmicedemonstratedrenalprotectionintheearly
phase of experimental IRI [39].
In summary, both the innate and adaptive immune
responses play critical roles in the pathophysiology of is-
chemic AKI. Either following antigen stimulation or in the
presence of proinﬂammatory chemokines and oxygen free
radicals, T cells undergo early activation and serve as a
bridge between adaptive and innate immunity. This speciﬁc
host immune response to kidney IRI facilitates distant organ
crosstalk along with soluble proinﬂammatory mediators and
will be further discussed in the following paragraphs.
3.EvolvingConceptsof OrganCrosstalk
duringIschemic AKI
3.1. Kidney-Lung Crosstalk. The combination of AKI with
acute lung injury (ALI) remains a formidable challenge to
clinicians caring for critically ill patients. In the setting of
MOF, AKI and ALI occur more frequently together than any
othercombinationoforgan systems, and predictedmortality
approaches 80% [40, 41]. This exceedingly high mortality
cannot be attributed solely to volume overload; leukocyte
traﬃcking, uremic toxins, and oxidative stress mechanisms
all likely contribute to this devastating clinical syndrome.
For the purposes of this paper, ALI represents a PaO2/FiO2
ratio <300combined with chest radiograph ﬁndings of acute
bilateral inﬁltrates in the absence of elevated cardiac ﬁlling
pressures, as deﬁned by the America-European Consensus
ConferenceonAcuteRespiratoryDistressSyndrome(ARDS)
[42].
While the mechanisms for ischemic AKI-induced ALI
remain incompletely understood, several studies point to-
ward a self-propagating cycle with activation of proinﬂam-
matory and proapoptotic pathways (Figure 2). AKI leads to
lunginjury andinﬂammation, and in turn,ALIand itsatten-
dant hypoxemia and hypercapnia worsened by mechanical
ventilation with high positive end-expiratory pressure leads
to diminishing renal hemodynamics and function. Lung
injury during ischemic AKI features marked pulmonary
vascular permeability, erythrocyte sludging in lung capil-
laries, interstitial edema, focal alveolar hemorrhage, and
inﬂammatory cell inﬁltration [12, 43, 44]. Mechanisms for
decreased alveolar ﬂuid clearance include downregulation of
pulmonary epithelial salt and water transporters including
ENaC, Na, K-ATPase, and aquaporins during ischemic
AKI [43–45]. This speciﬁc response likely contributes to
the increased microvascular permeability and clinical pul-
monary edema frequently encountered in the setting of is-
chemic AKI and MOF.
3.1.1. Role of Cytokines, Chemokines, and Leukocyte Traf-
ﬁcking. Experimental studies have identiﬁed a distinct pul-
monary functional response and genomic signature induced
during ischemic AKI which diﬀers from that induced by
uremia alone. A comprehensive genomic map and ontology
analysis revealed many of these top diﬀerentially expressed
genes participating in proinﬂammatory and proapoptotic
pathways. Genes with early and sustained activation at 6 and
36hours after ischemic AKI included neutrophilic granule
protein (Ngp), serum amyloid A3 (Saa3), and Interleukin 1-
receptor type II (Il-1r2) [12].
Further investigation by Deng et al. [13] has also iden-
tiﬁed an early pulmonary inﬂammatory response with
rapid activation of transcription factors NF-κBa n dA P - 1
during ischemic AKI. By 4 hours, lung expression of TNF-
α and ICAM-1 led to accumulation of pulmonary neu-
trophils. Leukocytes play a fundamental role in the devel-
opment of ALI, and several studies have documented lung
leukocyte activation and traﬃcking during experimental
AKI with early and sustained neutrophil sequestration
[46, 47]. Additional experiments by Klein et al. have
demonstrated early expression of the neutrophil che-
mokine keratinocyte-derived chemokine (KC/CXCL1) and
macrophage inﬂammatory protein (MIP-2/CXCL-2) along
with increased pulmonary myeloperoxidase activity and
pulmonary microvascular permeability during ischemic AKI
[45]. The authors also examined interleukin-6, a neutrophil-
recruiting chemokine previously identiﬁed as a candidate
gene by preferential expression in whole lung tissue during
ischemic AKI [48], and determined it was critical for inﬂu-
encing lymphocyte traﬃcking and pulmonary permeability
[45].
While neutrophils are key mediators in several extra-
pulmonary models of ALI such as sepsis and mesenteric
IRI, their role in ischemic AKI-induced ALI remains to be
elucidated. Uremic neutrophils have even demonstrated a
protective eﬀect in the setting of ALI [49]. Clearly, leukocyte
traﬃcking and the innate immune response play a complex
and important role in mediating the pulmonary inﬂamma-
tory response and dysfunction during renal IRI.
3.1.2. Lung Apoptosis. Though not traditionally associated
with a proinﬂammatory response, pulmonary apoptosis
plays a critical role in the genomic and phenotypic response
to ischemic AKI. Apoptosis of pulmonary epithelial and
endothelial cells along with delayed leukocyte apoptosis
occurs during ALI [50–52]. Pulmonary apoptosis dis-
rupts tethering forces involved in cell-to-cell and cell-to-
extracellularmatrixinteractions,leadingtoalossofendothe-
lial barrier function and increased vascular permeabilityInternational Journal of Nephrology 5
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Figure 2: PathologicalAxis between AKI and ALI. AKI induces pathophysiologiceﬀects on the lung via cellular and soluble mediators. ALI,
in turn, exacerbates kidney dysfunction through metabolic and biochemical derangements.
[53]. In a rodent model, our laboratory has characterized
caspase-dependent pulmonary apoptosis which is abrogated
by the administration ofa broad-spectrum caspase inhibitor.
Not only did caspase inhibition attenuate the pulmonary
functional injury, but the proapoptotic response to ischemic
AKIappears to be mediated via a TNF receptor-1 (TNF-R-1)
dependent pathway [54].
Our research has also demonstrated T-cell-dependent
pulmonary apoptosisduring ischemic AKI.Alongwith iden-
tiﬁcation of activated T cells traﬃcking to the lungs during
ischemic AKI, we have found that pulmonary apoptosis
was subsequently attenuated in T-cell-deﬁcient animals [33].
FurtherpursuitofthespeciﬁcpathwayforTcellandTNFR1-
dependent pulmonary apoptosis remains an active focus of
future investigation in our research laboratory.
3.2. Kidney Crosstalk with Other Distant Organs. Cardio-
vascular collapse is one of the most common causes of
death in the setting of AKI, yet the mechanisms involved
are not entirely understood [55]. Kelly has demonstrated left
ventricular dilation, increased left ventricular end diastolic
and end systolic diameter, increased relaxation time, and
decreased fractional shortening in an experimental model
of ischemic AKI [56]. Mechanisms of cardiac injury during
ischemic AKI include cardiac myocyte apoptosis and neu-
trophil inﬁltration, which have been attributed to increased
cardiac and systemic TNFα, IL-1, and ICAM-1 expression
[56, 57]. When kidney ischemic time is decreased, cardiac
IL-1 and ICAM expression, along with myocyte necrosis,
decreased correspondingly [56].
Eﬀects of ischemic AKI on the central nervous system
(CNS) are evident clinically when mental status changes
develop.Of note, renal replacement therapy fails to fully cor-
rect this CNSmanifestation ofrenal failure [58]. Uremictox-
ins certainly contribute to many symptoms of encephalopa-
thy; however, cellular and soluble inﬂammatory mediators
have also been implicated. Preclinical data identiﬁed an
increase of KC, G-CSF, and glial ﬁbrillary acidic protein
(GFAP)in thecerebral cortex and hippocampus ofthe brain,
which may serve to recruit neutrophils to sites of neuronal
damage [59]. This may result from either increased local
neuronal production or an alteration of the blood-brain
barrier; further research isrequired todelineate thesource. A
cell-mediated proinﬂammatory response has also been iden-
tiﬁed with activation of microglial cells (brain macrophages)
during ischemic AKI [59].
Ischemic AKI is also implicated in oxidative stress,
inﬂammation, apoptosis, and tissue damage in hepatocytes.
Hepatic stellate cells (HSCs) regulate leukocyte traﬃcking
and the secretion of chemokines such as IL-8, and crosstalk
between HSCs likely occurs via a c-Jun N-terminal kinase
pathway [60]. Oxidative stress during ischemic AKI causes
hepatic malondialdehyde, an index of lipid peroxidation, to
increase while total glutathione, an antioxidant, decreases
[61]. Proinﬂammatory cytokine TNFα expression and
hepatic cellular apoptosis is also evident during ischemic
AKI [61].6 International Journal of Nephrology
Previous investigators and clinicians have labeled the gut
as the “motor” of MOF because of its ability to amplify
the systemic SIRS response in the setting of shock and
gut hypoperfusion [62–64]. These mechanisms include
increased intestinal permeability, interactions between host
and bacterial pathogens, and propagation of toxins to
distant organs via the lymphatic system [63, 65]a n dc o u l d
potentially play a role during ischemic AKI. Clinical studies
havelong demonstrated theincreased secretion of potassium
by the colon and rectum in response to AKI [66], and
recent literature linked channel-inducing factor, a potassium
channel regulator found in both the kidney and colon, to
ischemic AKI[67,68].This may provideexplanation forwhy
hyperkalemia does not universally occur during AKI. The
role ofthe gutin response to organ crosstalk during ischemic
AKI remains a fascinating topic of future investigation.
4.Conclusion
AKI is a frequent complication amongst hospitalized pa-
tients, with grave implications in the setting of MOF.
Ischemic AKI initiates a cascade of proinﬂammatory path-
ways, and through the release of soluble mediators and acti-
vation of the host innate and adaptive immune systems, it
facilitates organ crosstalk and remote organ injury. As our
understandingofthepostischemic kidney’srolein mediating
organ crosstalk continues to evolve,further laboratory inves-
tigation into the remote organ response to this devastating
injury may reveal potential future therapeutic targets.
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